|
|
|
| A phase I study of gemcitabine combined with gamma knife therapy for locally advanced pancreatic cancer |
| YU Liquan1,CAO Jingxu1,CHENG Haimin2,YANG Yuanyou2,SHI Ming1,SONG Wei1,and WANG Yingxuan1. |
1.Department of Oncology 1,
2.Center of Gamma-knife Treatment, General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China |
|
|
|
|
Abstract Objective To estimate the optimal dose of gemcitabine administered concurrently with gamma knife therapy in patients with locally advanced pancreatic cancer. Method “3+3” model was measured in the study. Eligible patients had histologically confirmed pancreatic adenocarcinoma deemed locally unresectable. Patients received gamma knife therapy (52 Gy/13F) with concurrent infused weekly gemcitabine(dose escalated from 700 mg/m2 to 900 mg/m2 weekly) until dose-restricted toxicity. Results 9 patients were enrolled. Patients enrolled in gemcitabine 700 mg/m2 and 800 mg/m2 completed the plan.III-IV degree hematology toxicity was seen in patients when gemcitabine dose escalated to 900 mg/m2. Conclutions The combination of gemcitabine and gamma knife therapy is well tolerated. The optimal dose of gemcitabine is 800 mg/m2 weekly.
|
|
Received: 26 May 2013
|
|
|
|
|
|
|
|
|
2013, Vol. 24 
